Do different heparin brands influence activated clotting times?

Journal of Extra-Corporeal Technology

Volumn 30, Issue 2, 1998, Pages 73-76

  Dyck, Louise ^a,b   Friesen, Robert M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Activated clotting time; Cardiopulmonary bypass; Hepalean ; Heparin Leo ; Heparin sodium

Indexed keywords

HEPARIN; HEPARIN LEO; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DEVICE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; OXYGENATOR;

EID: 0031870111     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Thomas DP, Curtis AD, Barrowcliffe TWA. Collaborative study designed to establish the 4th international standard for heparin. Thromb Haemost. 1984; 52: 148-53.
2. British Pharmacopoeia. London: Her Majesty's Stationary Office. 1993: 320-3.
3. Drug information for the health care professional United States pharmacopeial dispensing information. USP23 1995: 736-8.
4. Hamilton M, MacDonald W, Levely A, Brister SJ, Buchanan MR. A rose is a rose - or is it? The 1993 Compendium of the Canadian Society of Clinical Perfusion, Scientific Sessions, October 1993.
5. Bauer TL, Arepally G, Konkle BA et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-46.